SMMT SMMT

The price pays for

• The FDA acceptance of the ivonescimab Biologics License Application with a November 2026 PDUFA date, treating the regulatory milestone as a known procedural step rather than a value-creating surprise.
• The positive 34% reduction in the risk of death from the HARMONi-6 trial in China, which is already reflected in the company's baseline expectations for the drug's efficacy.
• The current cash burn and the risk of future shareholder dilution, which the negative cash flow metrics and the bear-case model at $12 explicitly account for.
• The expectation of approximately $600 million in cash and investments by the end of 2026, providing a near-term financial floor that limits downside to the $12 bear target.

It declines to pay for